Pamela T Soliman1, Shannon N Westin2, Shayan Dioun2, Charlotte C Sun2, Elizabeth Euscher3, Mark F Munsell4, Nicole D Fleming2, Charles Levenback2, Michael Frumovitz2, Pedro T Ramirez2, Karen H Lu2. 1. Department of Gynecologic Oncology and Reproductive Medicine, University of Texas, M.D. Anderson Cancer Center, Houston, TX, United States. Electronic address: psoliman@mdanderson.org. 2. Department of Gynecologic Oncology and Reproductive Medicine, University of Texas, M.D. Anderson Cancer Center, Houston, TX, United States. 3. Department of Pathology, University of Texas, M.D. Anderson Cancer Center, Houston, TX, United States. 4. Division of Biostatistics, University of Texas, M.D. Anderson Cancer Center, Houston, TX, United States.
Abstract
OBJECTIVE: Sentinel lymph node (SLN) mapping continues to evolve in the surgical staging of endometrial cancer (EC). The purpose of this trial was to identify the sensitivity, false negative rate (FNR) and FN predictive value (FNPV) of SLN compared to complete pelvic and para-aortic lymphadenectomy (LAD) in women with high-risk EC. METHODS: Women with high-risk EC (grade 3, serous, clear cell, carcinosarcoma) were enrolled in this prospective surgical trial. All patients underwent preoperative PET/CT and intraoperative SLN biopsy followed by LAD. Patients with peritoneal disease on imaging or at the time of surgery were excluded. Patients were evaluable if SLN was attempted and complete LAD was performed. RESULTS: 123 patients were enrolled between 4/13 and 5/16; 101 were evaluable. At least 1 SLN was identified in 89% (90); bilateral detection 58%, unilateral pelvic 40%, para-aortic only 2%. Indocyanine green was used in 61%, blue dye in 28%, and blue dye and technetium in 11%. Twenty-three pts. (23%) had ≥1 positive node. In 20/23, ≥1 SLN was identified and in 19/20 the SLN was positive. Only 1 patient had bilateral negative SLN and positive non-SLNs on final pathology. Overall, sensitivity of SLN was 95% (19/20), FNR was 5% (1/20) and FNPV was 1.4% (1/71). If side-specific LAD was performed when a SLN was not detected, the FNR decreased to 4.3% (1/23). CONCLUSION: This prospective trial demonstrated that SLN biopsy plus side-specific LAD, when SLN is not detected, is a reasonable alternative to a complete LAD in high-risk endometrial cancer.
OBJECTIVE: Sentinel lymph node (SLN) mapping continues to evolve in the surgical staging of endometrial cancer (EC). The purpose of this trial was to identify the sensitivity, false negative rate (FNR) and FN predictive value (FNPV) of SLN compared to complete pelvic and para-aortic lymphadenectomy (LAD) in women with high-risk EC. METHODS:Women with high-risk EC (grade 3, serous, clear cell, carcinosarcoma) were enrolled in this prospective surgical trial. All patients underwent preoperative PET/CT and intraoperative SLN biopsy followed by LAD. Patients with peritoneal disease on imaging or at the time of surgery were excluded. Patients were evaluable if SLN was attempted and complete LAD was performed. RESULTS: 123 patients were enrolled between 4/13 and 5/16; 101 were evaluable. At least 1 SLN was identified in 89% (90); bilateral detection 58%, unilateral pelvic 40%, para-aortic only 2%. Indocyanine green was used in 61%, blue dye in 28%, and blue dye and technetium in 11%. Twenty-three pts. (23%) had ≥1 positive node. In 20/23, ≥1 SLN was identified and in 19/20 the SLN was positive. Only 1 patient had bilateral negative SLN and positive non-SLNs on final pathology. Overall, sensitivity of SLN was 95% (19/20), FNR was 5% (1/20) and FNPV was 1.4% (1/71). If side-specific LAD was performed when a SLN was not detected, the FNR decreased to 4.3% (1/23). CONCLUSION: This prospective trial demonstrated that SLN biopsy plus side-specific LAD, when SLN is not detected, is a reasonable alternative to a complete LAD in high-risk endometrial cancer.
Authors: Paul A Harris; Robert Taylor; Robert Thielke; Jonathon Payne; Nathaniel Gonzalez; Jose G Conde Journal: J Biomed Inform Date: 2008-09-30 Impact factor: 6.317
Authors: Robert W Holloway; Sarika Gupta; Nicole M Stavitzski; Xiang Zhu; Erica L Takimoto; Ajit Gubbi; Glenn E Bigsby; Lorna A Brudie; James E Kendrick; Sarfraz Ahmad Journal: Gynecol Oncol Date: 2016-03-02 Impact factor: 5.482
Authors: Joyce N Barlin; Qin Zhou; Caryn M St Clair; Alexia Iasonos; Robert A Soslow; Kaled M Alektiar; Martee L Hensley; Mario M Leitao; Richard R Barakat; Nadeem R Abu-Rustum Journal: Gynecol Oncol Date: 2013-06-14 Impact factor: 5.482
Authors: Katherine I Stewart; Beth Chasen; William Erwin; Nicole Fleming; Shannon N Westin; Shayan Dioun; Michael Frumovitz; Pedro T Ramirez; Karen H Lu; Franklin Wong; Thomas A Aloia; Pamela T Soliman Journal: Cancer Date: 2019-06-21 Impact factor: 6.860
Authors: Maria Luisa Gasparri; Donatella Caserta; Pierluigi Benedetti Panici; Andrea Papadia; Michael D Mueller Journal: J Cancer Res Clin Oncol Date: 2018-11-20 Impact factor: 4.553
Authors: Brooke A Schlappe; Amy L Weaver; Michaela E McGree; Jennifer Ducie; Ane Gerda Zahl Eriksson; Sean C Dowdy; William A Cliby; Gretchen E Glaser; Nadeem R Abu-Rustum; Andrea Mariani; Mario M Leitao Journal: Gynecol Oncol Date: 2019-11-24 Impact factor: 5.482
Authors: Francesco Multinu; Jvan Casarin; Serena Cappuccio; Gary L Keeney; Gretchen E Glaser; William A Cliby; Amy L Weaver; Michaela E McGree; Stefano Angioni; Gavino Faa; Mario M Leitao; Nadeem R Abu-Rustum; Andrea Mariani Journal: Gynecol Oncol Date: 2019-05-22 Impact factor: 5.482
Authors: Katherine I Stewart; Jarrod S Eska; Ross F Harrison; Rudy Suidan; Ann Abraham; Gary B Chisholm; Larissa A Meyer; Shannon N Westin; Nicole D Fleming; Michael Frumovitz; Thomas A Aloia; Pamela T Soliman Journal: Int J Gynecol Cancer Date: 2020-01-06 Impact factor: 3.437
Authors: Derman Basaran; Shaina Bruce; Emeline M Aviki; Jennifer J Mueller; Vance A Broach; Karen Cadoo; Robert A Soslow; Kaled M Alektiar; Nadeem R Abu-Rustum; Mario M Leitao Journal: Gynecol Oncol Date: 2019-11-16 Impact factor: 5.482
Authors: Natalia R Gómez-Hidalgo; Ling Chen; June Y Hou; Ana I Tergas; Caryn M St Clair; Cande V Ananth; Dawn L Hershman; Jason D Wright Journal: Cancer Invest Date: 2018-03-22 Impact factor: 2.176
Authors: Nicole Concin; Carien L Creutzberg; Ignace Vergote; David Cibula; Mansoor Raza Mirza; Simone Marnitz; Jonathan A Ledermann; Tjalling Bosse; Cyrus Chargari; Anna Fagotti; Christina Fotopoulou; Antonio González-Martín; Sigurd F Lax; Domenica Lorusso; Christian Marth; Philippe Morice; Remi A Nout; Dearbhaile E O'Donnell; Denis Querleu; Maria Rosaria Raspollini; Jalid Sehouli; Alina E Sturdza; Alexandra Taylor; Anneke M Westermann; Pauline Wimberger; Nicoletta Colombo; François Planchamp; Xavier Matias-Guiu Journal: Virchows Arch Date: 2021-02 Impact factor: 4.064